...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Free
Message: Zenith AGM - Q&A

There was also a question regarding whether or not DM saw ZEN3694 having to go through a Phase 2 or even 3 trial.  I believe the person was trying to determine if Zenith would try to take this further on their own (and thus the need for funding).  DM said something to the effect of "I sure hope not" which makes you think that they want to hand this off to someone else to take it to the finish line.

The "pre-IPO" comment didn't get much followup due to DM saying he needed to catch a plane (I thought I heard to Montreal?), but it seems to imply that they may actually list the company on an exchange.  Hmm.

masila

Share
New Message
Please login to post a reply